Issues
-
Cover Image
Cover Image
The microRNA network is considered to play critical roles in tumor progression; however, little information is available for microRNA in cancer stem-like cells (CSC). The results of microRNA profile analysis revealed that miR-7 is significantly downregulated in CSCs that are highly metastatic to the brain, and the expression of this microRNA significantly suppressed the ability of CSCs to metastasize to the brain in vivo. miR-7 was also found to be capable of modulating KLF4. Consistently, the expression of miR-7 and KLF4 in brain-metastatic lesions of breast cancer patients was found to be significantly downregulated and upregulated, respectively. High expression of KLF4 was also inversely correlated to brain-metastasis free survival of breast cancer patients. For details, see the article by Okuda and colleagues on page 1434. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Review
Clinical Studies
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Integrated Systems and Technologies
Microenvironment and Immunology
STC1 Expression By Cancer-Associated Fibroblasts Drives Metastasis of Colorectal Cancer
Molecular and Cellular Pathobiology
Inhibition of Cholinergic Signaling Causes Apoptosis in Human Bronchioalveolar Carcinoma
Therapeutics, Targets, and Chemical Biology
Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
Tumor and Stem Cell Biology
Letter to the Editor
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.